TY-1781 / TYK Medicines - LARVOL DELTA

TY-1781, a potent and highly selective CDK2 inhibitor, demonstrates superior anti-tumor activity in CCNE1 high-expression solid tumor models (AACR 2025) - "Background: The common prescription of Palbociclib and other approved CDK4/6 inhibitors in clinic have greatly benefitted breast cancer patients worldwide. Taken together, we identified a highly selective and potent CDK2 inhibitor through medicinal chemistry screening and rounds of refining. The data suggest that TY-1781 may be eligible for further clinical development for Cyclin E1 high-expression patients who relapse from previous standard of care treatments.# Chengshan Niu and Meihua Li contributed equally to this work.*To Whom Correspondence should be addressed to Shaoqing Chen, Chengshan Niu, Meihua Li and Jun Li."

Preclinical • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Gastric Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • CCNE1 • CDK1 • CDK7 • CDK9 • ER • HER-2